Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel
- 1 October 2005
- journal article
- clinical trial
- Published by Elsevier in Metabolism
- Vol. 54 (10) , 1276-1281
- https://doi.org/10.1016/j.metabol.2005.04.014
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide AutogelRClinical Endocrinology, 2004
- Population pharmacodynamic analysis of octreotide in acromegalic patientsClinical Pharmacology & Therapeutics, 2003
- Guidelines for Acromegaly ManagementJournal of Clinical Endocrinology & Metabolism, 2002
- Medical Management of Growth Hormone-Secreting Pituitary AdenomasPituitary, 2002
- Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of AcromegalyJournal of Clinical Endocrinology & Metabolism, 2002
- Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjectsPublished by Wiley ,2000
- Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)Journal of Clinical Endocrinology & Metabolism, 2000
- Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiencyClinical Pharmacology & Therapeutics, 1999
- Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release LanreotideJournal of Clinical Endocrinology & Metabolism, 1997
- Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study GroupJournal of Clinical Endocrinology & Metabolism, 1996